Shopping Cart
Remove All
Your shopping cart is currently empty
Quisovalimab (Synonyms: SAR 252067, MDGN-002, CERC-002, AVTX-002, AEVI 002)
Catalog No. T77136 Copy Product Info
🥰Excellent
Quisovalimab is a fully human monoclonal antibody that specifically binds to and neutralizes LIGHT(TNFSF14), a member of tumor necrosis factor superfamily, thus blocking its interaction with the receptor and inhibiting T cell-related inflammatory response. Quisovalimab has been used to study the inflammatory pathway mediated by LIGHT, and it has potential therapeutic value in COVID-19-related acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS).
Quisovalimab
Copy Product Info🥰Excellent
Catalog No. T77136
Synonyms SAR 252067, MDGN-002, CERC-002, AVTX-002, AEVI 002
Quisovalimab is a fully human monoclonal antibody that specifically binds to and neutralizes LIGHT(TNFSF14), a member of tumor necrosis factor superfamily, thus blocking its interaction with the receptor and inhibiting T cell-related inflammatory response. Quisovalimab has been used to study the inflammatory pathway mediated by LIGHT, and it has potential therapeutic value in COVID-19-related acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS).
Quisovalimab
Cas No. 2427667-03-4
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $647 | 2-4 weeks | 2-4 weeks | |
| 10 mg | $987 | 2-4 weeks | 2-4 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Quisovalimab is a fully human monoclonal antibody that specifically binds to and neutralizes LIGHT(TNFSF14), a member of tumor necrosis factor superfamily, thus blocking its interaction with the receptor and inhibiting T cell-related inflammatory response. Quisovalimab has been used to study the inflammatory pathway mediated by LIGHT, and it has potential therapeutic value in COVID-19-related acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS). |
| Synonyms | SAR 252067, MDGN-002, CERC-002, AVTX-002, AEVI 002 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Target | LIGHT |
| Cas No. | 2427667-03-4 |
| Isotype | IgG4 (S228P) |
| Recommended Isotype Control |
| Storage | Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Preview
Related Tags: buy Quisovalimab | purchase Quisovalimab | Quisovalimab cost | order Quisovalimab
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.